What's new

Opinion/decision on a Paediatric investigation plan (PIP): Entyvio, vedolizumab, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Gastrointestinal disorders, PIP number: P/0244/2024

Opinion/decision on a Paediatric investigation plan (PIP): Entyvio, vedolizumab, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Gastrointestinal disorders, PIP number: P/0244/2024

Jun 24, 2025 - 15:10
 0
Opinion/decision on a Paediatric investigation plan (PIP): Entyvio, vedolizumab, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Gastrointestinal disorders, PIP number: P/0244/2024
Opinion/decision on a Paediatric investigation plan (PIP): Entyvio, vedolizumab, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Gastrointestinal disorders, PIP number: P/0244/2024
Read More

Tags:

Previous Article

Human medicines European public assessment report (EPAR): Jemperli, dostarlimab,...

Next Article

Human medicines European public assessment report (EPAR): Perjeta, pertuzumab, D...

Related Posts

Human medicines European public assessment report (EPAR): Uzpruvo, ustekinumab, Date of authorisation: 05/01/2024, Revision: 7, Status: Authorised

Human medicines European public assessment report (EPAR...

May 16, 2025  0

Human medicines European public assessment report (EPAR): Datroway, datopotamab deruxtecan, Date of authorisation: 04/04/2025, Revision: 1, Status: Authorised

Human medicines European public assessment report (EPAR...

Jun 24, 2025  0

Epidemiological data on blood transmissible infections - Scientific guideline

Epidemiological data on blood transmissible infections ...

Jun 19, 2025  0